Selected research
Industry Research
VLP Vaccines Industry Research Report 2026
Market perspective
The global VLP Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for VLP Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for VLP Vaccines is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for VLP Vaccines is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of VLP Vaccines include H&Z Life Science, Merck, Gproan, VLP Therapeutics, VBI, Spybiotech, Saiba Animal Health, POSVAX and Optipharm Co. Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global VLP Vaccines market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
VLP Vaccines Market by Company
H&Z Life Science
Merck
Gproan
VLP Therapeutics
VBI
Spybiotech
Saiba Animal Health
POSVAX
Optipharm Co. Ltd
Novavax
Medicago
ARTES Biotechnology
VLP Vaccines Segment by Type
Hepatitis B Vaccine
Covid-19 Vaccine
HPV Vaccine
Others
VLP Vaccines Segment by Application
Government
Medical Institution
Others
VLP Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global VLP Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of VLP Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of VLP Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of VLP Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of VLP Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of VLP Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Hepatitis B Vaccine
- Covid-19 Vaccine
- HPV Vaccine
- Others
Applications
- Government
- Medical Institution
- Others
Companies covered
- H&Z Life Science
- Merck
- Gproan
- VLP Therapeutics
- VBI
- Spybiotech
- Saiba Animal Health
- POSVAX
- Optipharm Co. Ltd
- Novavax
- Medicago
- ARTES Biotechnology
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global VLP Vaccines Market Size (2021-2032)
- 2.2.2 Global VLP Vaccines Sales (2021-2032)
- 2.2.3 Global VLP Vaccines Market Average Price (2021-2032)
- 2.3 VLP Vaccines by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Hepatitis B Vaccine
- 2.3.3 Covid-19 Vaccine
- 2.3.4 HPV Vaccine
- 2.3.5 Others
- 2.4 VLP Vaccines by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Government
- 2.4.3 Medical Institution
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global VLP Vaccines Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global VLP Vaccines Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global VLP Vaccines Revenue of Manufacturers (2021-2026)
- 3.4 Global VLP Vaccines Average Price by Manufacturers (2021-2026)
- 3.5 Global VLP Vaccines Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of VLP Vaccines, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of VLP Vaccines, Product Type & Application
- 3.8 Global Manufacturers of VLP Vaccines, Established Date
- 3.9 Global VLP Vaccines Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 H&Z Life Science
- 4.1.1 H&Z Life Science Company Information
- 4.1.2 H&Z Life Science Business Overview
- 4.1.3 H&Z Life Science VLP Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 H&Z Life Science VLP Vaccines Product Portfolio
- 4.1.5 H&Z Life Science Recent Developments
- 4.2 Merck
- 4.2.1 Merck Company Information
- 4.2.2 Merck Business Overview
- 4.2.3 Merck VLP Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck VLP Vaccines Product Portfolio
- 4.2.5 Merck Recent Developments
- 4.3 Gproan
- 4.3.1 Gproan Company Information
- 4.3.2 Gproan Business Overview
- 4.3.3 Gproan VLP Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Gproan VLP Vaccines Product Portfolio
- 4.3.5 Gproan Recent Developments
- 4.4 VLP Therapeutics
- 4.4.1 VLP Therapeutics Company Information
- 4.4.2 VLP Therapeutics Business Overview
- 4.4.3 VLP Therapeutics VLP Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 VLP Therapeutics VLP Vaccines Product Portfolio
- 4.4.5 VLP Therapeutics Recent Developments
- 4.5 VBI
- 4.5.1 VBI Company Information
- 4.5.2 VBI Business Overview
- 4.5.3 VBI VLP Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 VBI VLP Vaccines Product Portfolio
- 4.5.5 VBI Recent Developments
- 4.6 Spybiotech
- 4.6.1 Spybiotech Company Information
- 4.6.2 Spybiotech Business Overview
- 4.6.3 Spybiotech VLP Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Spybiotech VLP Vaccines Product Portfolio
- 4.6.5 Spybiotech Recent Developments
- 4.7 Saiba Animal Health
- 4.7.1 Saiba Animal Health Company Information
- 4.7.2 Saiba Animal Health Business Overview
- 4.7.3 Saiba Animal Health VLP Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Saiba Animal Health VLP Vaccines Product Portfolio
- 4.7.5 Saiba Animal Health Recent Developments
- 4.8 POSVAX
- 4.8.1 POSVAX Company Information
- 4.8.2 POSVAX Business Overview
- 4.8.3 POSVAX VLP Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 POSVAX VLP Vaccines Product Portfolio
- 4.8.5 POSVAX Recent Developments
- 4.9 Optipharm Co. Ltd
- 4.9.1 Optipharm Co. Ltd Company Information
- 4.9.2 Optipharm Co. Ltd Business Overview
- 4.9.3 Optipharm Co. Ltd VLP Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Optipharm Co. Ltd VLP Vaccines Product Portfolio
- 4.9.5 Optipharm Co. Ltd Recent Developments
- 4.10 Novavax
- 4.10.1 Novavax Company Information
- 4.10.2 Novavax Business Overview
- 4.10.3 Novavax VLP Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Novavax VLP Vaccines Product Portfolio
- 4.10.5 Novavax Recent Developments
- 4.11 Medicago
- 4.11.1 Medicago Company Information
- 4.11.2 Medicago Business Overview
- 4.11.3 Medicago VLP Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Medicago VLP Vaccines Product Portfolio
- 4.11.5 Medicago Recent Developments
- 4.12 ARTES Biotechnology
- 4.12.1 ARTES Biotechnology Company Information
- 4.12.2 ARTES Biotechnology Business Overview
- 4.12.3 ARTES Biotechnology VLP Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 ARTES Biotechnology VLP Vaccines Product Portfolio
- 4.12.5 ARTES Biotechnology Recent Developments
5 Global VLP Vaccines Market Scenario by Region
- 5.1 Global VLP Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global VLP Vaccines Sales by Region: 2021-2032
- 5.2.1 Global VLP Vaccines Sales by Region: 2021-2026
- 5.2.2 Global VLP Vaccines Sales by Region: 2027-2032
- 5.3 Global VLP Vaccines Revenue by Region: 2021-2032
- 5.3.1 Global VLP Vaccines Revenue by Region: 2021-2026
- 5.3.2 Global VLP Vaccines Revenue by Region: 2027-2032
- 5.4 North America VLP Vaccines Market Facts & Figures by Country
- 5.4.1 North America VLP Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America VLP Vaccines Sales by Country (2021-2032)
- 5.4.3 North America VLP Vaccines Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe VLP Vaccines Market Facts & Figures by Country
- 5.5.1 Europe VLP Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe VLP Vaccines Sales by Country (2021-2032)
- 5.5.3 Europe VLP Vaccines Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific VLP Vaccines Market Facts & Figures by Country
- 5.6.1 Asia Pacific VLP Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific VLP Vaccines Sales by Country (2021-2032)
- 5.6.3 Asia Pacific VLP Vaccines Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America VLP Vaccines Market Facts & Figures by Country
- 5.7.1 South America VLP Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America VLP Vaccines Sales by Country (2021-2032)
- 5.7.3 South America VLP Vaccines Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa VLP Vaccines Market Facts & Figures by Country
- 5.8.1 Middle East and Africa VLP Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa VLP Vaccines Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa VLP Vaccines Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global VLP Vaccines Sales by Type (2021-2032)
- 6.1.1 Global VLP Vaccines Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global VLP Vaccines Sales Market Share by Type (2021-2032)
- 6.2 Global VLP Vaccines Revenue by Type (2021-2032)
- 6.2.1 Global VLP Vaccines Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global VLP Vaccines Revenue Market Share by Type (2021-2032)
- 6.3 Global VLP Vaccines Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global VLP Vaccines Sales by Application (2021-2032)
- 7.1.1 Global VLP Vaccines Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global VLP Vaccines Sales Market Share by Application (2021-2032)
- 7.2 Global VLP Vaccines Revenue by Application (2021-2032)
- 7.2.1 Global VLP Vaccines Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global VLP Vaccines Revenue Market Share by Application (2021-2032)
- 7.3 Global VLP Vaccines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 VLP Vaccines Value Chain Analysis
- 8.1.1 VLP Vaccines Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 VLP Vaccines Production Mode & Process
- 8.2 VLP Vaccines Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 VLP Vaccines Distributors
- 8.2.3 VLP Vaccines Customers
9 Global VLP Vaccines Analyzing Market Dynamics
- 9.1 VLP Vaccines Industry Trends
- 9.2 VLP Vaccines Industry Drivers
- 9.3 VLP Vaccines Industry Opportunities and Challenges
- 9.4 VLP Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst